Trials / Completed
CompletedNCT01885598
Eliquis Regulatory Post Marketing Surveillance
Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,335 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban |
Timeline
- Start date
- 2013-07-10
- Primary completion
- 2017-09-29
- Completion
- 2017-09-29
- First posted
- 2013-06-25
- Last updated
- 2017-10-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01885598. Inclusion in this directory is not an endorsement.